Publicaciones en colaboración con investigadores/as de Hospital del Mar (15)

2024

  1. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study

    The Lancet Haematology, Vol. 11, Núm. 8, pp. e606-e616

2023

  1. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry

    Biomedicines, Vol. 10, Núm. 1

2021

  1. High penetrance of inferior vena cava system atresia in severe thrombophilia caused by homozygous antithrombin Budapest 3 variant: Description of a new syndrome

    American Journal of Hematology, Vol. 96, Núm. 11, pp. 1363-1373

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

  2. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines

    Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098

2013

  1. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: Clonal evolution and hierarchy revealed by next-generation sequencing

    Journal of Hematology and Oncology, Vol. 6, Núm. 1

2012

  1. Assessment and prognostic value of the European leukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

    Blood, Vol. 119, Núm. 6, pp. 1363-1369

2010

  1. Antithrombin Murcia (K241E) causing antithrombin deficiency: A possible role for altered glycosylation

    Haematologica, Vol. 95, Núm. 8, pp. 1358-1365

  2. Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody

    Thrombosis and Haemostasis, Vol. 104, Núm. 6, pp. 1143-1149

  3. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

    Blood, Vol. 116, Núm. 8, pp. 1205-1210

2009

  1. ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders

    Blood Coagulation and Fibrinolysis

  2. Análisis retrospectivo de la eficacia y la tolerabilidad de anagrelida en pacientes con trombocitemia esencial: Registro español de trombocitemia esencial

    Medicina Clinica, Vol. 133, Núm. 3, pp. 86-90

2008

  1. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia

    Annals of Hematology

  2. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury

    Critical Care Medicine, Vol. 36, Núm. 2, pp. 526-534